Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Generic challenges, the next first-to-files, GDUFA dues (FY 2016) and more
PharmaCompass has assessed the second quarter US Drug Master
File (DMFs) filings. In our view, with